Pharmacotherapy for Alzheimer's disease: Progress and prospects

Trends in Pharmacological Sciences

Volumn 23, Issue 9, 2002, Pages 426-433

  Palmer, Alan M ^a  

^a Pharmidex   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; GALANTAMINE; KETAMINE; MUSCARINIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHYSOSTIGMINE; RIVASTIGMINE; SCOPOLAMINE; TACRINE; XANOMELINE;

ALZHEIMER DISEASE; BEHAVIOR; CLINICAL TRIAL; COGNITION; DISEASE COURSE; DRUG EFFECT; HUMAN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BEHAVIOR; COGNITION DISORDERS; HUMANS; NEUROFIBRILLARY TANGLES;

EID: 0036710570     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)02056-4     Document Type: Review

References (77)

1. Mayeux R., Sano M. Treatment of AD. New Engl. J. Med. 341:1999;1670-1679.
2. Fox N.C., et al. Imaging of onset and progression of AD with voxel-compression mapping of serial magnetic resonance images. Lancet. 358:2001;201-205.
3. Pearson R.C. Cortical connections and the pathology of Alzheimer's disease. Neurodegeneration. 5:1996;429-434.
4. Rub U., et al. The autonomic higher order processing nuclei of the lower brain stem are among the early targets of the Alzheimer's disease-related cytoskeletal pathology. Acta Neuropathol. 101:2001;555-564.
5. Hebert L.E., et al. Age-specific incidence of Alzheimer's disease in a community population. J. Am. Med. Assoc. 273:1995;1354-1359.
6. Palmer A.M., Gershon S. Is the neurochemical basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J. 4:1990;2745-2752.
7. Francis P.T., et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry. 66:1999;137-147.
8. Sarter M., Bruno J.P. Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers. Behav. Brain Res. 83:1997;7-14.
9. Levy J.A., et al. Acetylcholine affects the spatial scale of attention: evidence from Alzheimer's disease. Neuropsychology. 14:2000;288-298.
10. Moghul S., Wilkinson D. Use of acetylcholinesterase inhibitors in Alzheimer's disease. Expert Rev. Neurotherapeutics. 1:2001;61-69.
11. Benzi G., Moretti A. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? Eur. J. Pharmacol. 346:1988;1-13.
12. Palmer A.M. Neurochemical studies of Alzheimer's disease. Neurodegeneration. 5:1996;381-391.
13. Francis P.T., et al. Cortical pyramidal neuron loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J. Neurochem. 60:1993;1589-1604.
14. Kullmann D.M., et al. The role of mammalian ionotropic receptors in synaptic plasticity: LTP, LTD and epilepsy. Cell. Mol. Life Sci. 57:2000;1551-1561.
15. Blennow K., et al. Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J. Neural Transm. 103:1996;603-618.
16. Hampson R.E., et al. Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J. Neurosci. 18:1998;2740-2747.
17. Cummings J.L. Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. Neurobiol. Aging. 21:2000;845-861.
18. Hope T., et al. Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study. Br. J. Psychiatry. 174:1999;39-44.
19. Jacobs B.L., Fornal C.A. Serotonin and motor activity. Curr. Opin. Neurobiol. 7:1997;820-825.
20. Aston-Jones G., et al. Role of locus coeruleus in attention and behavioral flexibility. Biol. Psychiatry. 46:1999;1309-1320.
21. Vetulani J., Nalepa I. Antidepressants: past, present and future. Eur. J. Pharmacol. 405:2000;351-363.
22. Oquendo M.A., Mann J.J. Serotonergic dysfunction in mood disorders. Med. Psychiatry. 15:2000;121-142.
23. Matthews K., et al. Noradrenergic changes, aggressive behavior and cognition in patients with dementia. Biol. Psychiatry. 23:2002;407-416.
24. Fridman E.A., et al. Treatment of depression in patients with dementia: epidemiology, pathophysiology and treatment. CNS Drugs. 14:2000;191-201.
25. Naslund J., et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. J. Am. Med. Assoc. 283:2000;1571-1577.
26. Tanzi R.E., Bertram L. New frontiers in Alzheimer's disease genetics. Neuron. 32:2001;181-184.
27. Fassbender K., et al. Alzheimer's disease: molecular concepts and therapeutic targets. Naturwissenschaften. 88:2001;261-267.
28. Scorer C.A. Preclinical and clinical challenges in the development of diseseas-modifying therapies for Alzheimer's disease. Drug Discov. Today. 6:2001;1207-1219.
29. Sisodia S.S., et al. γ-secretase: never more enigmatic. Trends Neurosci. 24:2001;S2-S6.
30. Golde T.E., Younkin S.G. Presenilins as therapeutic targets for the treatment of Alzheimer's disease. Trends Mol. Med. 7:2001;264-269.
31. Dovey H.F., et al. Functional gamma-secretase inhibitors reduce β-amyloid peptide levels in brain. J. Neurochem. 76:2001;173-181.
32. Schenk D., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
33. Bard F., et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919.
34. Lemere C.A., et al. Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. New York Acad. Sci. 920:2000;328-331.
35. Check E. Need for vaccine stocks questioned. Nature. 414:2001;677.
36. Cherny R.A. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 30:2001;665-676.
37. Spillantini M.G., Goedert M. Tau gene mutations and tau pathology in frontotemporal dementia and parkinsonism linked to chromosome 17. Adv. Exp. Med. Biol. 487:2001;21-37.
38. Buée L., et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev. 33:2000;95-130.
39. van Slegtenhorst M., et al. The molecular genetics of the tauopathies. Exp. Gerontol. 35:2000;461-471.
40. Berg L., et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol. 55:1998;326-335.
41. Thal D., et al. Alzheimer-related τ-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia. Exp. Neurol. 163:2000;98-110.
42. Palmer A.M. The activity of the pentose phosphate pathway is increased in response to oxidative stress in Alzheimer's disease. J. Neural Transm. 106:1999;317-328.
43. Sano M., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. New Engl. J. Med. 336:1997;1216-1222.
44. Behl C., Moosmann B. Estrogens and other antioxidants in neuroprotection: implications for Alzheimer's disease. Oxid. Stress Dis. 5:2000;467-485.
45. Mulnard R.A. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. J. Am. Med. Assoc. 283:2000;1007-1015.
46. Palmer A.M. Excitatory amino acids and neurodegeneration. Front. Neurobiol. 3:1998;195-226.
47. Blass J.P., et al. Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise. Ann. New York Acad. Sci. 903:2000;204-221.
48. Mattson M.P., et al. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann. New York Acad. Sci. 893:1999;154-175.
49. Finch C.E. Inflammation in Alzheimer's disease. Mol. Mech. Neurodegen. Dis. 1:2001;87-110.
50. Lucca U. Nonsteroidal anti-inflammatory drugs and Alzheimer's disease: update on recent data and their therapeutic implications. CNS Drugs. 11:1999;207-224.
51. Weggen S., et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature. 414:2001;212-216.
52. Lim G.P., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20:2000;5709-5714.
53. Golde T.E., Eckman C.B. Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. Drug Discov. Today. 6:2001;1049-1055.
54. Hartmann T. Cholesterol, Aβ and Alzheimer's disease. Trends Neurosci. 24:2001;S45-S48.
55. Dawson D.A., et al. A comparative assessment of the efficacy and side effect liability of neuroprotective compounds in experimental stroke. Brain Res. 892:2001;344-350.
56. Danysz W., et al. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease-a unified glutamatergic hypothesis on the mechanism of action. Neurotoxic. Res. 2:2000;85-97.
57. Thal L.J. Trials to slow progression and prevent disease onset. J. Neural Transm. 59:2000;243-249.
58. Brookmeyer R., et al. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health. 88:1998;1337-1342.
59. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropath. 82:1991;239-259.
60. Palmer A.M., et al. Excitatory amino acid releasing and cholinergic neurones in Alzheimer's disease. Neurosci. Lett. 66:1986;199-204.
61. Kish S.J., et al. Non-Alzheimer-type pattern of brain cholineacetyltransferase reduction in dominantly inherited olivopontocerebellar atrophy. Ann. Neurol. 26:1989;362-367.
62. Davis K.L., et al. Cholinergic markers in elderly patients with early signs of Alzheimer. J. Am. Med. Assoc. 281:1999;1401-1406.
63. Gilmor M.L., et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J. Comp. Neurol. 411:1999;693-704.
64. Tiraboschi P., et al. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology. 55:2000;1278-1283.
65. Bierer L.M., et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J. Neurochem. 64:1995;749-760.
66. Francis P.T., et al. Neurochemical studies in early-onset Alzheimer's disease: possible influence on treatment. New Engl. J. Med. 313:1985;7-11.
67. Baskin D.S., et al. Brain choline acetyltransferase and mental function in Alzheimer disease. Arch. Neurol. 56:1999;1121-1123.
68. Neary D., et al. Alzheimer's disease: a correlative study. J. Neurol. Neurosurg. Psychiatry. 49:1986;229-237.
69. Bejar C., et al. Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur. J. Pharmacol. 383:1999;231-240.
70. Poorheidari G., et al. Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits in the delayed matching to position task in rats: a comparison with the cholinesterase inhibitor E2020. Psychopharmacology (Berl.). 135:1998;242-255.
71. Stanhope K.J., et al. Dissociation between cognitive and motor/motivational deficits in the delayed matching to position test: effects of scopolamine, 8-OH-DPAT and EAA antagonists. Psychopharmacology (Berl.). 122:1995;268-280.
72. Dunne M.P., Hartley L.R. Scopolamine and the control of attention in humans. Psychopharmacology (Berl.). 89:1986;94-97.
73. Hagan J.J., et al. Place navigation in rats is impaired by lesions of medial septum and diagonal band but not nucleus basalis magnocellularis. Behav. Brain Res. 27:1988;9-20.
74. van der Staay F.J., et al. Selective fimbria lesions impair acquisition of working and reference memory of rats in a complex spatial discrimination task. Behav. Brain Res. 32:1989;151-161.
75. Dunnett S.B., et al. The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions. Trends Neurosci. 14:1991;494-501.
76. Grutzendler J., Morris J.C. Cholinesterase inhibitors for Alzheimer's disease. Drugs. 61:2001;41-52.
77. Benzi G., Moretti A. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? Eur. J. Pharmacol. 346:1998;1-13.